Deloitte Adjusts Employee Health Benefits in Response to Healthcare Cost Surge
Deloitte's recent adjustments to its U.S. employee health benefits reflect a growing trend among corporations grappling with rising healthcare costs.
In a strategic move that matches industry patterns, Deloitte announced it will stop covering GLP-1 medications for weight-loss under its health plans. This comes at a time when the use of these drugs, particularly semaglutide and tirzepatide, has surged for weight management. The medications will still be covered when prescribed for diabetes or other approved medical needs. The decision was communicated via an internal benefits guide, highlighting an industry-wide reevaluation of how healthcare expenses are shared between employers and employees.
Increased Financial Responsibilities for Employees
Alongside changes in medication coverage, Deloitte employees will see higher deductibles and out-of-pocket maximums across most health plans. These adjustments are aimed at sharing the financial burden as health insurance costs climb. Deloitte remains committed to mitigating these changes by offering a virtual lifestyle program, eMed, supporting weight-loss efforts with coaching and a financial contribution of $125 per prescription. Despite this support, the list prices for medications can exceed $1,000, posing challenges for some employees.
Broader Industry Shifts
Deloitte's decisions mirror those of other major corporations like PwC and Starbucks, which have similarly revised their GLP-1 medication policies. According to a 2026 health benefits survey, conducted by KFF, there has been a marked increase in average premiums paid by both workers and employers. Meanwhile, an Aon study highlights that 39% of employers plan to limit GLP-1 coverage by 2026.
| Company | GLP-1 Coverage Change |
|---|---|
| Deloitte | Ends weight-loss coverage Maintains for diabetes |
| PwC | Revamped coverage policies for weight-loss |
| Starbucks | Adjusted weight-loss drug coverage |
Strategic Revisions Amid Broader Challenges
These developments underscore a balancing act faced by companies: controlling operational costs while maintaining competitive employee benefits. A spokesperson from Deloitte emphasized the necessity of these changes due to sustaining cost growth challenges. Deloitte also reported slower revenue growth in its Americas division, which plays into the broader strategy of balancing employee benefits with operational expenses.
The Path Forward
These changes affect most client-facing roles within Deloitte's "Core, Domain, and Enterprise professionals" segments, impacting around 181,000 U.S. employees. As employers continue to navigate this complex landscape, further adjustments in policies related to health, parental leave, and other benefits are expected. For the insurance sector, the story underscores evolving challenges and opportunities in managing coverage, pricing, and strategic planning against a backdrop of escalating healthcare demands.